ISCO International Stem Cell CORP
Pharmaceutical Preparations · OTC · SEC CIK 1355790 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.4%
TTM net income YoY-141.5%
TTM EPS YoY-75.0%
Revenue 3-yr CAGR5.7%
Net income 3-yr CAGR—
Margins
Gross margin55.0%
Operating margin-4.7%
Net margin-6.1%
FCF margin3.5%
EBITDA margin-2.9%
Returns
ROE—
ROA-11.0%
ROIC (approx.)—
Asset turnover1.79x
Leverage & solvency
Liabilities / assets98.6%
Debt / equity—
Current ratio0.79x
Interest coverage-3.15x
Cash quality & payout
Operating cash flow / net income-0.63x
Accruals ratio-17.9%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $9.10M | $9.09M |
| Cost of revenue | $4.03M | $3.76M |
| Gross profit | $5.07M | $5.32M |
| R&D expense | $684,000 | $657,000 |
| SG&A expense | $3.53M | $3.52M |
| Operating income | -$267,000 | -$68,000 |
| Interest expense | $151,000 | $145,000 |
| Pretax income | -$418,000 | -$209,000 |
| Income tax | $0 | $0 |
| Net income | -$418,000 | -$209,000 |
| EBITDA | -$48,000 | $138,000 |
| EPS (basic) | -0.05 | -0.03 |
| EPS (diluted) | -0.05 | -0.03 |
| Weighted avg. shares (diluted) | 8.00M | 8.00M |
| Balance sheet | ||
| Cash & equivalents | $993,000 | $1.23M |
| Receivables | $723,000 | $1.06M |
| Inventory | $1.51M | $1.15M |
| Current assets | $3.41M | $3.56M |
| PP&E, net | $160,000 | $257,000 |
| Intangibles | $644,000 | $721,000 |
| Total assets | $4.82M | $5.17M |
| Current liabilities | $4.58M | $4.69M |
| Total liabilities | $4.58M | $4.80M |
| Shareholders' equity | -$4.06M | -$3.93M |
| Shares outstanding | 8.00M | 8.00M |
| Cash flow statement | ||
| Operating cash flow | $8,000 | $13,000 |
| Capital expenditure | $43,000 | $166,000 |
| Free cash flow | -$35,000 | -$153,000 |
| Investing cash flow | -$45,000 | -$171,000 |
| Financing cash flow | -$200,000 | -$200,000 |
| Depreciation & amortization | $219,000 | $206,000 |
| Stock-based compensation | $288,000 | $466,000 |
Free plan shows the latest 2 periods; Pro shows all 20 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.